PMVP News | Roxom Stocks

Invest Private Security Newsroom

Market Overview

Indices and commodities.

Bitcoin treasury preferreds.

The artificial intelligence theme.

Bitcoin Treasuries

Companies holding bitcoin.

Sectors, global markets and rates.

Popular Portfolios

13F filings, smart money.

Borrow USDT or USDC against your BTC without giving it up.

Switch your bitcoin-backed loan and pay less interest.

Borrow, invest, keep the spread.

Stock Dividends

Dividends from tokenized equities.

Company

Our leadership team, mission, and investors.

Vision, purpose, and architecture behind Roxom.

Terms, privacy, and disclosures.

Resources

Guides, FAQs & support.

Trading logic, platform rules, and fundamentals.

Connect, authenticate, and build with our API.

Current platform health and incidents.

Loading chart

Pay with

1 BTC

=

- USD

Loading market data...

Loading chart

Pay with

PM

Volume

350.94K

Next Earnings

November 11th

Loading chart

PM

PMVPPMV Pharmaceuticals, Inc

PMVP

Pay with—

Available Balance0.00

PM

Mkt Cap

$69.0M

Volume

350.94K

Next Earnings

November 11th

Chart Financials Earnings News About Insider Filings

PMVP Stock Rises 19% in 3 Months: Here's What You Need to KnowPMV Pharmaceuticals (PMVP) has gained nearly 19% in three months following encouraging clinical data for its lead drug rezatapopt, which achieved a 46% response rate in ovarian cancer patients. The company plans to submit an NDA in Q1 2027 and raised $50.8 million through a public offering to fund operations into Q1 2028.Zacks Investment Research · Oct 12, 2026

PMV Pharma Announces Pricing of Oversubscribed $50 Million Public Offering of SecuritiesPMV Pharma announced a public offering of 22.055 million shares of common stock and pre-funded warrants to purchase 19.9 million shares, along with accompanying warrants, expected to raise approximately $50.8 million gross proceeds. The offering is priced at $1.21 per share and is expected to close on or about September 2, 2026.GlobeNewswire Inc. · Sep 1, 2026

PMV Pharmaceuticals Announces Board Chair TransitionPMV Pharmaceuticals announced a leadership transition with Laurie Stelzer, a director since 2020, appointed as the new Board Chair, succeeding Rich Heyman effective June 4, 2026. Stelzer brings over 25 years of senior finance and business development experience in biopharmaceuticals. The transition occurs as the company continues enrollment in its PYNNACLE clinical trial for rezatapopt and prepares to submit a New Drug Application for platinum-resistant/refractory ovarian cancer patients in Q1 2027.GlobeNewswire Inc. · Apr 22, 2026

PMV Pharmaceuticals Reports Full Year 2025 Financial Results and Corporate HighlightsPMV Pharmaceuticals reported positive Phase 2 interim data from its PYNNACLE trial evaluating rezatapopt for platinum-resistant/refractory ovarian cancer with TP53 Y220C mutations, achieving a 50% overall response rate among 48 evaluable patients. The company received FDA Orphan Drug Designation and plans to submit a New Drug Application in Q1 2027. However, cash runway extends only to Q2 2027 with $112.9 million in reserves, and the company increased R&D spending while net losses widened to $77.7 million in 2025.GlobeNewswire Inc. · Mar 6, 2026

Here's Why PMV Pharmaceuticals (PMVP) Could be Great Choice for a Bottom FisherPMV Pharmaceuticals (PMVP) appears to have found support after losing some value lately, as indicated by the formation of a hammer chart. In addition to this technical chart pattern, strong agreement among Wall Street analysts in revising earnings estimates higher enhances the stock's potential for a turnaround in the near term.Zacks Investment Research · Jun 3, 2024

Foundation Medicine and PMV Pharma Announce Collaboration to Develop Companion Diagnostic for Rezatapopt, a First-In-Class, Investigational, Selective p53 Y220C ReactivatorBOSTON and PRINCETON, N.J., May 29, 2024 (GLOBE NEWSWIRE) -- Foundation Medicine, Inc. and PMV Pharmaceuticals, Inc. (NASDAQ: PMVP; “PMV Pharma”) today announced a partnership to develop Foundation Medicine’s tissue-based comprehensive genomic profiling test, FoundationOne®CDx, as a companion diagnostic for PMV Pharma’s rezatapopt, a first-in-class, investigational therapy for patients with locally advanced or metastatic solid tumors that have a TP53 Y220C mutation.GlobeNewswire Inc. · May 29, 2024

Here's Why You Should Buy Acrivon Therapeutics (ACRV) StockHere, we discuss some reasons why buying Acrivon Therapeutics (ACRV) stock now may turn out to be a prudent move.Zacks Investment Research · May 28, 2024

PMV Pharmaceuticals PYNNACLE Phase I Data of Rezatapopt in Advanced Ovarian Cancer Featured in Late-Breaking Oral Presentation at 2024 SGO Annual Meeting on Women’s CancerPRINCETON, N.J., March 18, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today announced that a Phase 1 analysis reported promising anti-tumor activity of rezatapopt (PC14586) in heavily pre-treated patients with advanced ovarian cancer harboring a TP53 Y220C mutation. Rezatapopt is a first-in-class precision oncology small molecule investigational therapy that selectively targets the TP53 Y220C mutation in solid tumors.GlobeNewswire Inc. · Mar 18, 2024

PMV Pharmaceuticals Reports Full Year 2023 Financial Results and Corporate HighlightsPRINCETON, N.J., Feb. 29, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor-agnostic therapies targeting p53, today reported financial results for the fourth quarter and full year ended December 31, 2023, and provided a corporate update.GlobeNewswire Inc. · Feb 29, 2024

PMV Pharmaceuticals Announces Prioritization of PC14586 Clinical Development and Extended Cash RunwayPRINCETON, N.J., Jan. 18, 2024 (GLOBE NEWSWIRE) -- PMV Pharmaceuticals, Inc. (Nasdaq: PMVP), a precision oncology company pioneering the discovery and development of small molecule, tumor agnostic therapies targeting p53, today announced a strategic reduction of its workforce by approximately 30%. PMV will maintain a focused discovery research effort and expects that the resulting savings in operating expenses will extend its cash runway to the end of 2026.GlobeNewswire Inc. · Jan 18, 2024

to start trading

PM

PMVPPMV Pharmaceuticals, Inc

PMVP

Pay with—

Available Balance0.00

Your PositionYou don't own any PMVP yet.

Related Tickers

Earnings